Pulmonary delivery of insulin by dry powder inhaler formulations.
The results confirmed that the pulmonary formulations could deliver and release insulin molecules in a good manner, and the biological activity of the two formulations, including F1 and F3, is acceptable and comparable to the subcutaneous insulin. Our findings support that the mentioned DPI products could have therapeutic potential as an alternative to subcutaneous insulin. Further investigations are needed to prove the capability of F1 and F3 spray-dried products to treat diabetic individuals.
Authors
- Gholamreza Karimi (ORCID: https://orcid.org/0000-0002-1273-5448)
- Mohsen Tafaghodi (ORCID: https://orcid.org/0000-0002-8286-0973)
- Mohsen Imenshahidi (ORCID: https://orcid.org/0000-0002-2441-0421)
- Khalil Abnous (ORCID: https://orcid.org/0000-0001-6314-0164)
- Mona Kabiri (ORCID: https://orcid.org/0000-0002-8702-9409)
- Mohammad Jandaghi
- Seyed Salman Razavi Rouhani
Institutions
- Mashhad University of Medical Sciences (IR)
Publication Details
- Journal
- PubMed
- Published
- 2025-01-01
- DOI
- https://doi.org/10.22038/ijbms.2025.83954.18168
- Citations
- 1
- Primary Topic
- Inhalation and Respiratory Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Mashhad University of Medical Sciences